Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|The Lancet Oncology|2025Cited by 13
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY StudyTitouan Cazaubiel, Cyrille Hulin, Bruno Royer et al.|Clinical Hematology International|2025Cited by 2
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 TrialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|SSRN Electronic Journal|2025Cited by 1
Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.Enrico Maffini, Mohamad Mohty, Igor Wolfgang Blau et al.|Blood|2025Cited by 1